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Introduction
Our understanding and treatment of complement-mediated dis-
eases has grown exponentially over the last 20 years. We now 
understand that complement plays an integral role in many auto-
immune- and inflammation-based diseases or conditions (1). The 
identification of hyperactive complement as the primary driver 
in atypical hemolytic uremic syndrome (aHUS) (2) and its large-
ly successful treatment using eculizumab (3, 4) has revealed the 
potential of anti-complement therapy in the treatment of many 
diseases, such as age-related macular degeneration (AMD), auto-
immune disorders, and neurodegenerative conditions (5). Howev-
er, eculizumab is not a panacea in AMD (6) or rheumatic diseases 
(7) or even in aHUS (8). Thus, there remains a need for better mod-
els of complement-mediated diseases to trial drugs and dissect the 
molecular pathways that are common among complement-medi-
ated/associated diseases.
The complement system, consisting of more than 50 proteins, 
is integral to defense against pathogens and for maintenance of host 
homeostasis. It is considered the backbone of innate immunity, as it 
is critical in microbial killing, apoptotic cell clearance, and immune 
complex handling (9). Key complement proteins are activated in a 
stepwise manner through an enzymatic activation cascade that is 
regulated by an array of modulators (10). Activation can be achieved 
through one or more of the classical, lectin, and alternative pathways, 
all of which culminate in the cleavage of C3. Cleavage of C3 (185 kDa) 
into C3b (177 kDa) and C3a (8 kDa) is the central activating step of the 
complement cascade (11). C3 cleavage leads to deposition of C3b onto 
the surface of microbes (opsonization), release of the proinflammato-
ry anaphylactic products C3a and C5a, and initiation of the terminal 
pathway, leading to the formation of the membrane attack complex 
(MAC) C5b-9 and cell lysis (12). Given the intricate nature of the 
complement cascade, many soluble and membrane-associated pro-
teins function to regulate C3 activation (13). Together these protect 
healthy host cells and tissues from unwanted complement activation, 
while unprotected surfaces rapidly become coated in C3b molecules 
(1). Abnormalities in the complement system, derived by genetic or 
acquired means, are associated with a variety of pathologies (14).
aHUS is a renal disease that encompasses the clinical triad 
of microangiopathic hemolytic anaemia, thrombocytopenia, and 
acute renal failure (15). Dysregulation of the alternative pathway 
of the complement system at the cell or extracellular matrix sur-
face is a major factor in susceptibility to aHUS (16). In particular, 
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pathway (31). In theory, with time, patients on C5-inhibiting thera-
py could convert their phenotype from aHUS to a C3- mediated glo-
merular disease (e.g., complement 3 glomerulopathy [C3G]; refs. 
32, 33) as opposed to a C5/terminal pathway–mediated disease. 
Lifelong C5 inhibition poses a significant immunosuppressive 
burden on the patient (34), particularly patients who have renal 
transplants and are already on triple immunosuppressive therapy 
(35). While previous (24) and existing mouse models based on FH 
functional deficit (36, 37) display some of the characteristic phe-
notypes/pathologies of aHUS, reflecting potential subsets of the 
disease, they do not entirely reproduce the clinical observations, 
i.e., disease induction required either nephrotoxic serum (36) or 
was driven by excessive coagulation/thrombosis (37).
Herein, we describe the transfer of human C3 gain-of-func-
tion aHUS-associated mutations to murine C3. Following in vitro 
characterization of these murine C3 mutants, we introduced a 
point mutation in murine C3 (p.D1115N) in conditional knockin 
mice. C57BL/6 mice homozygous for C3 Asn1115 (C3KI) exhibit a 
spontaneous aggressive renal phenotype that is identical to aHUS 
as described in humans. Ex vivo analysis confirmed that failure to 
bind FH could explain the pathogenicity of this point mutant. C5 
blockade protected C3KI mice from disease, and through long-
term studies of C5 genetic deletion, we have shown that while 
increased C3 turnover continues through dysregulation of the 
alternative pathway, this does not evolve into a C3 glomerulopa-
thy. Given that our model robustly recapitulates the clinical phe-
notype in humans, this allows us to translate our long-term studies 
in mice to humans — providing insight into the effects of chronic 
terminal pathway inhibition on the alternative pathway. This C3 
gain-of-function mouse model of aHUS thus provides an opportu-
nity for anti-complement drug testing.
Results
Natural history of a familial C3 Asn1115 mutation discovered in the 
NRCTC aHUS cohort. The C3 Asn1115 point mutation has been 
identified in 3 families, including in the NRCTC/Paris aHUS 
patient cohort (Figure 1A) (26). The patients are heterozygous 
for a missense mutation in C3 (C3 c.3343 G>A), corresponding 
to replacement of an aspartic acid with an asparagine at position 
1115 of C3 (D1115N, Figure 1B; note this is D1093N in the mature 
protein) (15, 26, 28). The C3 Asn1115 variant has a substantial loss 
in binding to both MCP (CD46) and FH (26, 29), which we con-
firmed in additional surface plasmon resonance (SPR) analysis 
(Supplemental Figure 1; supplemental material available online 
with this article; https://doi.org/10.1172/JCI99296DS1). Despite 
almost complete loss of interaction with MCP, we hypothesized 
that the loss of interaction of the C-terminal region FH with the 
TED of this C3b (the cleaved, activated form of C3) variant, as 
illustrated in Figure 1B, would be important for selective rec-
ognition of a self-surface (38), which could be critical for the 
pathogenicity of the mutation. The chronological clinical param-
eters of creatinine and C3, FB, and FH of the family carrying the 
Asn1115 mutation are presented as available (Figure 1, C and D). 
One patient has a functioning renal transplant (28). This patient 
received the transplant before the era of preemptive eculizum-
ab for kidney transplantation, and when graft function started 
to decline, a biopsy confirmed features of a chronic thrombot-
an imbalance between the activators and regulators of the alter-
native pathway results in complement-mediated damage to the 
endothelium (17). Approximately 60% of individuals with aHUS 
have at-risk mutations in their complement genes (4). Mutations 
occur either in the genes encoding complement-regulating pro-
teins such as factor H (FH), factor I (FI), and membrane cofactor 
protein (MCP) or in genes encoding complement-activation pro-
teins (C3 and factor B [FB]) (18). In general, it has been observed 
that disease-linked mutations in regulators result in a loss of 
function, while disease-linked mutations in activators result in a 
gain of function (19). The most frequently mutated gene in aHUS 
patients is CFH (the gene encoding FH), occurring in 25% of spo-
radic cases, followed by mutations in C3 (4%–11% of cases), in CFI 
(5%–10%), in MCP (5%–9%), and in FB (<4%) (20).
The nature of the genetic complement abnormality has a sig-
nificant impact on the clinical phenotype. Those with mutations in 
MCP have the best prognosis (only 6% reach end-stage renal fail-
ure [ESRF]), while mutations in CFH have historically been asso-
ciated with the worst prognosis, including earlier disease onset 
and higher risk of relapse (20). CFH mutations typically cluster 
in exons 22 and 23 of CFH, which encode the C-terminal short 
consensus repeats (SCRs; also referred to as complement con-
trol protein domains [CCPs]) 19–20 of FH (21, 22). This region is 
important for regulating C3b amplification on host cell and tissue 
surfaces, while the N-terminal region SCRs 1–4 are important for 
regulatory activity both in the fluid phase and on surfaces (21, 23). 
The functional significance of the SCRs 19–20 was elegantly illus-
trated through transgenic expression of an FH truncation protein 
that lacked the C-terminal 5 SCRs backcrossed onto FH-knockout 
mice (24). These mice spontaneously developed features mirror-
ing aHUS in humans. This observation indicated that regulation 
in the fluid phase (preventing futile depletion of C3 in plasma) 
combined with dysregulation at the cell surface was pathogenic 
in aHUS. Further work confirmed the damage caused by down-
stream events in the complement cascade, since the phenotype 
could be rescued by breeding onto a C5-deficient background (25). 
We have known for some time that gain-of-function C3 mutations, 
clustering in the FH-binding interface of C3b, are associated with 
aHUS (26). Interestingly, mutations in C3 have varied outcomes, 
with 63%–67% of adult patients progressing rapidly to ESRF and 
some C3 mutations (including D1115N) resulting in chronic pro-
gression (27, 28), a renal prognosis similar to that seen with many 
CFH mutations (15). As SCRs 19–20 of FH bind to the thioester 
domain (TED) of C3b, it was expected that in vitro studies would 
confirm that recombinant human C3 proteins with mutations 
located in the TED (mature C3 p.D1093N, p.C1136W, p.Q1139K, 
p.A1072V) were defective in binding to FH (26, 29). This reduced 
binding affinity was proposed to cause reduced proteolytic inacti-
vation and therefore enhanced complement activation in vivo. To 
date, however, no in vivo studies have examined C3 gain-of-func-
tion aHUS mutations. Consequently, a direct demonstration that 
these mutations cause aHUS has been lacking.
The historical work in animal models, coupled with the suc-
cessful use of C5 inhibitors in aHUS patients, lays the foundation 
for our current understanding of the pathogenesis of aHUS (30). 
However, what is not yet known is the effects of long-term C5 inhi-
bition in the presence of continued dysregulation of the alternative 
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to develop a new animal model. Initially, we needed to test the fea-
sibility of transferring mutations in human C3 and their functional 
outcomes to murine C3. A pairwise sequence alignment confirmed 
that all mutated C3 residues identified in our earlier study (26) 
and several others identified later (29) were conserved in mouse 
C3, with the exception of R102 (Supplemental Figure 2A). Indeed, 
this pattern of residue conservation was noted across rat (P01026), 
bovine (Q2UVX4), pig (P01025), and guinea pig (P12387) C3 
proteins (Supplemental Figure 2B). For ease of purification, we 
designed a cDNA construct to allow production of recombinant 
FLAG- and 7xHis-tagged murine C3 (NM_009778.3) in mamma-
lian tissue culture (see Supplemental Methods and Supplemental 
Figure 3). After sequence confirmation of the recombinant mouse 
C3 (rmC3) construct, we used site-directed mutagenesis to gener-
ate 10 mutant rmC3 clones. These included 923ΔDG rmC3, based 
ic microangiopathy (TMA; Figure 1, E and F). In the context of 
low-grade hemolysis, eculizumab treatment was commenced for 
recurrent aHUS (Figure 1C). This was successful, with no further 
deterioration in allograft function to date (albeit chronic damage 
had already occurred prior to the use of eculizumab). Notably in 
this patient, FH plasma levels were found to be above the upper 
limits of the normal range for the majority of the time points ana-
lyzed, while FB levels were below the normal range (Figure 1C), 
providing evidence of increased alternative pathway activation.
Successful generation and functional testing of recombinant mouse 
C3 and several disease-associated mutants. Data generated in vitro 
with mutant human C3 molecules have suggested that some are 
resistant to control by FH (26, 29), but there has been no direct in 
vivo demonstration that mutations in C3, including those identified 
in the Newcastle patients, cause aHUS. To address this, we sought 
Figure 1. The NRCTC family heterozygous for C3 Asn1115 mutation. (A) Family pedigree showing affected individuals. (B) Location of the C3 mutation 
(D1115N) within the activated C3b fragment. The structure shown is the complex of human C3b, human FI, and mini-FH (SCRs 1–4 and SCRs 19–20, of 
human FH, connected by a poly-Gly linker) (5o32.pdb). C3b (blue) and FI (pink) are shown as cartoons, and mini-FH (gray) as a surface. The side chain 
atoms of C3b residue D1115 are shown as red spheres. CUB, complement C1r/C1s, Uegf, Bmp1. (C) Complement profile and renal events of II:1. Where avail-
able, C3 levels (top panel) with lower reference range (dotted line); FB levels (middle panel) with lower reference range (dashed line); and FH levels (bottom 
panel) with upper reference range (black dash-dotted line) are shown over more than 30 years. Associated clinical features are indicated above: ERSD and 
received first renal allograft, fourth year after transplant; Δ indicates declining graft function as a result of chronic allograft nephropathy; the second and 
third renal allografts are indicated by τ2 and τ3, respectively, with asterisk highlighting loss of third renal allograft to recurrent aHUS with increased creat-
inine and treatment with eculizumab (Ecul). (D) Where available, C3 and creatinine levels of individual II:3; C3 level in red (right y axis), and renal function 
in black; Δ indicates chronic TMA on biopsy followed by ESRD as indicated. (E) Representative H&E staining of II:3 showing double contouring (a feature 
of TMA); original magnification, ×40. (F) Electron micrograph from II:3 shows a capillary loop with detachment of the endothelium with accumulation of 
electron lucent material; original magnification, ×8000.
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mice were bred onto constitutive Cre-expressing mice (B6Tm1Cre/Oz), 
heterozygous (C3KI/WT) and homozygous (C3KI) mice were read-
ily identified by genotype PCR (Figure 2A). Subsequent analysis of 
F2 litters showed that proportions of specific genotypes were in line 
with expectations (20% WT versus 28% C3KI, with no influence 
on sex; Supplemental Figure 7A) from a normal Mendelian mode 
of inheritance, indicating that the D1115N mutation in C3 did not 
affect embryo survival in utero. At weaning (aged 18–21 days), many 
C3KI mice weighed less than their littermates (Supplemental Figure 
7B), and by postpartum day 50 (P50) they exhibited significantly (P 
< 0.0001) higher mortality (Figure 2B). Analysis of plasma from 
C3KI/WT and C3KI mice showed the presence of intact mutant C3 
protein and some evidence of C3 breakdown fragments, i.e., C3d, 
but not complete loss of intact C3 as observed in FH-deficient mice 
(Figure 2, C and D). See complete unedited blots in the supplemen-
tal material. Similar evidence was noted with respect to FB con-
sumption (Supplemental Figure 7C). We suspect that C3b amplifica-
tion is less well regulated, leading to an increased rate of conversion 
of C3 Asn1115 to C3b Asn1115 and low C3 levels (68 ± 5 μg/ml C3KI 
versus 365± 41 μg/ml for WT). However, the degree of C3 consump-
tion/fragment generation was significantly lower than that seen in 
on the previous findings of gain of function for this mutant associ-
ated with C3 glomerulopathy (Supplemental Figure 2C) (39). The 
recombinant proteins were purified to homogeneity using FLAG-
tag affinity chromatography and examined by SDS-PAGE (Supple-
mental Figure 4). Using standard fluid-phase cofactor assays, we 
found evidence that rmC3b (Val1072) and rmC3b (Asn1115), in 
comparison to WT rmC3b, demonstrated clear resistance to pro-
teolytic inactivation by FI (Supplemental Figure 4). Furthermore, 
using SPR (Biacore), several of our C3b mutants had reduced bind-
ing to “mini” murine FH (mini-FH; a construct containing the 2 key 
C3b-binding sites, i.e., SCRs 1–5 and SCRs 18–20 of murine FH), 
with rmC3(Asn1115) having one of the lowest-affinity interactions 
in this assay (Supplemental Figure 5). This is entirely consistent 
with loss of an important H-bonding interaction with Tyr1190 of 
FH as described by Morgan et al. (38). To explore the in vivo conse-
quence of C3 gain-of-function changes, we next generated a condi-
tional knockin mouse (C3KI) based on the Asn1115 change.
Development of the C3KI model. Possession of a form of C3b that 
cannot be recognized by FH is expected to be embryonically lethal 
(40). Thus, C3KI mice were generated using conditional knockin 
technologies (Ozgene; see Supplemental Figure 6). When these 
Figure 2. Initial characterization of C3KI mice. (A) A representative ethidium bromide–stained PCR gel illustrating genotyping of C3KI mice, with the SalI 
digest, as appropriate, indicated by SI below the gel. (B) Kaplan-Meier survival curve analysis of the first 44 C3KI and C3KI/WT littermates (F1–F3). Data for 44 
WT littermates were identical to those for C3KI/WT. (C) Western blots of murine C3 derived from plasma (freshly collected into EDTA and run under reduced 
conditions) detected by goat anti–mouse C3 (MP Biomedicals). Mouse genotype is indicated above the lanes; each lane represents an individual mouse. Che-
miluminescence image were captured using LI-COR Odyssey FC and displayed in pseudo-color. (D) Plasma murine C3 levels from 11 WT (gray circles), 6 knockin 
(KI)/WT (black squares), 15 KI (red triangles), and 16 FH-KO (black hexagons) mice were measured. Absorbance readings at 450 nm were converted to μg/ml 
using a standard curve based on purified mouse C3; mean ± SEM. ***P < 0.001 and ****P < 0.0001 using unpaired t test with Welch’s correction.
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14 to 28 days old, was consistent with histological features typical 
of a chronic TMA, including mesangiolysis (Figure 4A), followed 
by microaneurysm formation resulting from the dissolution of the 
mesangial matrix (Figure 4B) and double contouring of the glo-
merular basement membrane (Figure 4C). Electron microscopy 
confirmed endothelial injury with loss of fenestrations and suben-
dothelial lucency (Figure 4D). Fibrin deposition within glomeruli 
was observed in C3KI mice, and occasionally, intravascular throm-
boses were identified (Supplemental Figure 7, D–I). Interestingly, 
we did not see any histological evidence of a TMA in the C3KI/WT 
mice (Supplemental Figure 8, A–C), MAHA (Supplemental Figure 
8D), or kidney disease even after a year (Supplemental Figure 8E).
Complement dysregulation of C3KI. Having identified an 
aggressive renal disease in the C3KI mice, coupled with the histo-
logical analysis showing a TMA (in keeping with aHUS), we inves-
tigated the complement profile of the C3KI mice. Interestingly, 
plasma FH levels in C3KI mice were elevated (Figure 5A). This is 
consistent with a response to higher levels of complement activa-
tion or regulation (37). Additionally, plasma C5 levels were low-
er in C3KI mice (Figure 5B). Significant C3 fragment deposition 
was identified using immunofluorescence staining (Figure 5C). A 
granular staining pattern, largely confined to the mesangium and 
capillary walls of the glomerulus, was clearly evident in the C3KI 
the FH-deficient mouse, where very little intact C3 was detectable 
in isolated plasma (15 ± 3 μg/ml; Figure 2, C and D) (36, 41).
Characterization of C3KI mice. Analysis of survival curves 
showed clearly that (homozygous) C3KI mice, but not (heterozy-
gous) C3KI/WT mice, had a higher mortality than WT mice. We 
therefore decided to track C3KI mice from P7. C3KI mice were 
smaller than littermates at all stages of analysis, and many C3KI 
mice displayed heavy proteinuria and significant hematuria (Fig-
ure 3, A and B). Creatinine levels (reflecting renal impairment) 
were elevated in the majority of C3KI mice, but were highest in 
mice in the final stages of disease, as expected (Figure 3C). Addi-
tionally, urea levels, another surrogate marker of renal dysfunc-
tion, were elevated in the majority of C3KI mice (Figure 3D). 
Platelet counts were lower in C3KI mice, and very sick animals 
presented with severe thrombocytopenia (Figure 3E). Blood films 
from C3KI mice contained schistocytes, indicating fragmentation 
of red blood cells (Figure 3F). The presence of schistocytes cou-
pled with the observation of thrombocytopenia are consistent with 
microangiopathic hemolytic anemia, a salient feature of aHUS.
TMA in C3KI mice. C3KI mice had renal disease, as evidenced 
by proteinuria, hematuria and elevated creatinine, and a propor-
tion reached ESRF, requiring euthanasia. Periodic acid–Schiff 
(PAS) staining of kidney sections, from C3KI mice ranging from 
Figure 3. Further characterization of the C3KI mice. Where available, levels of proteinuria (A) and hematuria (B) were measured by Combistix (Siemens/
Bayer) analysis of urine collected during routine handling. Results for 13 C3KI (triangles), 24 C3KI/WT (squares), and 8 WT (circles) mice, P14–P21, are 
shown. (C) Creatinine values obtained from the mouse plasma taken from 19 C3KI, 34 C3KI/WT heterozygous, and 19 WT mice, P14–P28, are shown. (D) 
Urea values obtained from plasma taken from 13 C3KI mice, 4 C3KI/WT, and 4 WT mice. (E) Platelet counts of 8 C3KI, 12 C3KI/WT, and 5 WT mice on P21. 
Absolute numbers were provided by use of cell count beads and flow cytometry. (F) A representative (n = 8, P21) Giemsa-stained blood film from a C3KI 
mouse showing schistocytes (indicated by black arrows), consistent with mechanical hemolysis of red blood cells. Original magnification ×40. *P < 0.05, 
**P < 0.01, ***P < 0.005 using unpaired t test with Welch’s correction.
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mice. This was distinct from the C3KI/WT and WT littermates, in 
which tubulointerstitial staining was observed (which is normal in 
murine kidneys; refs. 24, 37). Detection of C9 (Figure 5D) in the 
glomeruli of C3KI mice, by immunofluorescence staining, sug-
gested that terminal pathway activation and MAC deposition con-
tribute to disease in the C3KI mice, as also happens during aHUS 
in humans. No glomerular C9 deposition was found in the kidney 
of C3KI/WT or WT mice (Figure 5D).
Molecular basis for complement dysregulation. Based on our work 
using rmC3 (Supplemental Figures 4 and 5), we expected C3 isolat-
ed from the blood of C3KI mice to have lower affinity, compared 
with WT murine C3, for FH. To confirm this, we isolated and puri-
fied C3 Asn1115 protein from knockin mice to homogeneity, and 
purified WT C3 as well as full-length FH from C57BL/6 mice. In 
addition, we generated recombinant mouse FH1–5, mouse Crry, 
and human FH19–20 (see Supplemental Methods for details). 
Using SPR, we measured the strength of the interaction between 
WT murine C3b or murine C3b Asn1115 (generated by incubation 
with human FB and FD; see Methods; 930 ± 10 RU amine coupled 
to a CM5 chip) and regulatory proteins or protein fragments. Full-
length mouse serum–derived FH bound to WT C3 with an affinity 
(KD) of 1.4 ± 0.13 μM, while it bound C3b Asn1115 with a KD of 3.7 
± 0.25 μM (Figure 6A). Recombinant mouse FH1–5 bound to both 
WT C3b and C3b Asn1115 with essentially equivalent affinity (2.9 ± 
0.24 μM and 3.1 ± 0.34 μM, respectively; Figure 6B). These values 
are broadly similar to the affinity of full-length mouse FH binding 
to C3b Asn1115, and hence, taken together, these SPR data suggest 
the almost complete loss of binding between mutant C3 and the 
C-terminus of FH. We confirmed this using SPR to measure the 
binding between human FH19–20 (42, 43) (the analyte) and vari-
ous versions of mouse C3b. FH19–20 bound WT C3b with a KD of 
9.4 ± 1.2 μM (43), whereas it bound immobilized C3b Asn1115 with a 
much weaker KD (saturation was not reached) of >17.4 (Figure 6C). 
Finally, as Crry is the major cell surface regulator of complement 
in the mouse, we also evaluated its binding to WT and mutant C3b 
and found that recombinant mouse Crry bound to WT C3b and C3b 
Asn1115 with essentially equivalent affinity (3.2 ± 0.03 μM and 3.5 ± 
0.06 μM, respectively; Figure 6D). Finally, fluid-phase FI cofactor 
assays, with purified reagents, indicated that C3b Asn1115 was more 
resistant to cleavage by human FI (with murine FH as cofactor) than 
WT murine C3b (Figure 6, E and F). These data are thus consistent 
with a mechanism whereby alternative pathway dysregulation in 
C3KI mice, arising from a perturbation of the binding site in C3b for 
the self/non-self-discriminatory C-terminal region of FH, is respon-
sible for a TMA within the kidney and an aHUS-like phenotype in 
the mouse.
Reversing complement dysregulation in C3KI mice. The data pre-
sented above suggest that C3KI mice provide a unique model of 
complement-mediated disease that arises from a gain-of-function 
mutation rather than a loss-of-function change in complement 
regulators. The current gold standard treatment for comple-
ment-mediated aHUS in humans is eculizumab. We reasoned that 
treatment of C3KI mice with a C5-blocking mAb should protect 
them from developing aHUS.
Therefore, we injected P13–P30 C3KI mice with 50 μg/g 
BB5.1 (a C5-inhibiting mAb, with dosing based on previous 
studies; refs. 44, 45), for up to 2 weeks and compared them with 
C3KI mice dosed with isotype-control antibody (mouse IgG1/
PBS). While 55% (6 of 11) of mice treated with the control anti-
body were removed from the study due to poor health, none of 
the mice treated with BB5.1 (0 of 8) succumbed to disease (Fig-
ure 7A). Failure to thrive, as indicated by low weight gain, was 
also partially reversed in BB5.1-treated mice compared with 
isotype controls (Supplemental Figure 9). Creatinine values 
were lower in the BB5.1 treatment arm, reflecting attenuation 
of renal injury, or else signs of renal recovery (Figure 7B). Plate-
let counts were significantly higher in the animals treated with 
BB5.1 (Figure 7C). C3 immunofluorescence appeared similar in 
both treatment arms, but C9 glomerular deposition was lower 
in the BB5.1 treatment arm (Figure 7D). Despite the marked 
clinical recovery in the BB5.1-treated cohort, histological anal-
ysis revealed only subtle improvement over the treatment peri-
od, with some persisting pathological features in both treated 
and control cohorts (Figure 7E). In general, an improvement 
in hematological outcomes for C3KI mice was achieved by C5 
inhibition, consistent with a major role for the complement cas-
cade in this mouse model of aHUS.
Genetic deficiency in C5 protects mice from all kidney disease. 
To further validate the model and provide translational insight 
into long-term C5 blockade, we backcrossed the C3KI onto the 
Figure 4. TMA in C3KI mice. PAS-stained sections from C3KI mice aged 
14–28 days. Images are representative of the 8 C3KI mice examined. 
Arrows highlight key examples of the following: (A) Mesangiolysis in the 
glomerulus. (B) Microaneurysms of the glomerular capillaries following 
dissolution of the matrix after the mesangiolysis. (C) Double contour-
ing of glomerular capillary walls, a key feature of chronic TMA. Original 
magnification in A–C, ×40. (D) Electron microscopy (original magnification, 
×7900) showing subendothelial lucency, which is consistent with ischemic 
conditions precipitated by the TMA from a day 7 C3KI mouse.
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C5-deficient mice (C5KO). As expected there was 100% surviv-
al of the C3KI.C5KO mice. Two cohorts of mice were tracked 
and culled at 2 and 6 months, respectively. No evidence of 
proteinuria was detected in urine collected before mice were 
culled in either cohort (Figure 8A and Supplemental Figure 
10A), and creatinine levels were similar to those in age- and lit-
termate-matched controls (Figure 8B and Supplemental Figure 
10B). Collectively, these observations indicate a lack of chronic 
kidney disease. Plasma C3 levels remained low in C3KI.C5KO 
mice (118 ± 6 μg/ml) (Supplemental Figure 10C). This was par-
ticularly evident in the 6-month-old animals (84 ± 8 μg/ml) 
when compared with C3KI mice (68 ± 8 μg/ml) or C5KO mice 
(281 ± 60 μg/ml) (Figure 8C). Nevertheless, levels of C3 in the 
C3KI.C5KO mice were significantly (P < 0.0001) higher than 
the levels reported in the FH-KO mice (current model of C3 glo-
merulopathy), where all the fluid-phase C3 had been consumed 
(Figure 2C; ref. 41). As might be surmised from the low plasma 
C3 levels, glomerular C3 fragment deposition was still evident 
in both cohorts (Figure 8D and Supplemental Figure 10, D and 
E), while C9 staining was absent (Figure 8D, lower panels). The 
C3 fragment deposition in C3KI.C5KO mice did not appear to 
lead to morphological features of C3 glomerulopathy, as glom-
eruli appeared normal in the Martius scarlet blue– (MSB-) and 
PAS-stained sections (Figure 8, E and F, and Supplemental Fig-
ure 10, F–I). This was further validated using electron micros-
copy, whereby 6-month C3KI.C5KO mice showed healthy 
glomeruli and no evidence of electron-dense deposits (Figure 
8G), similar to aged-matched WT (Figure 8H) and in contrast to 
6-month FH-KO animals, which showed pathological features 
of C3 glomerulopathy (Supplemental Figure 10J). Peripheral 
blood smears showed no evidence of schistocytes in the C3KI.
C5KO mice (Figure 8I and Supplemental Figure 10K).
Figure 5. Complement dysregulation in C3KI mice. (A) Complement FH levels in mouse plasma isolated from 19 C3KI mice (triangles), 34 C3KI/WT 
(squares), and 19 WT (circle) mice, P14–28, were established using an in-house sandwich ELISA described in Methods. (B) C5 levels in mouse plasma 
isolated from 17 C3KI, 15 C3KI/WT, and 8 WT mice on P14–P28 were established using an in-house sandwich ELISA. Relative units were generated via 
a standard curve based on WT control serum. (C) Immunofluorescence of glomerular C3 deposition in C3KI, C3KI/WT, and WT kidneys (representative 
of n = 10 in each group). Images were taken on a Zeiss Axio Imager II. Original magnification, ×20. Densitometry analysis is shown to the right of the 
panels; relative fluorescence units from >25 image captures are indicated. (D) Glomerular C9 deposition in C3KI in comparison to background staining 
of WT. Original magnification ×20; >6 image captures shown in densitometry. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 using unpaired t 
test with Welch’s correction.
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humans. The relative health of the heterozygous mice (C3KI/WT) 
despite markedly increased complement turnover also offers the 
potential to investigate how C3 activity shapes the progression of 
other complex genetic disorders, such as rheumatic and neuro-
logical conditions, including AMD. In short, the development of 
this precision, rapid, and spontaneous model of complement dys-
regulation, in conjunction with subsequent strategic backcrosses, 
has the potential to provide platforms to carry out preclinical test-
ing of drugs (anti-complement in particular) for the treatment of 
patients with a wide variety of complement-mediated diseases.
FHΔSCR16–20–transgenic mice (24) established that deletion 
of the FH C-terminus and its self-surface-binding capabilities, com-
bined with uncompromised FH N-terminus–mediated control of C3 
depletion in fluid phase, allows development of an aHUS-like dis-
ease. This study was fully consistent with the discovery that most 
Discussion
This study demonstrates that transferring a disease-associated 
single-nucleotide substitution in C3, present in a family within the 
NRCTC aHUS cohort, to murine C3 faithfully recapitulated the 
salient features of the human disease. Indeed, it could be argued 
that the resultant mouse model of aHUS, with respect to disease 
pathology, represents a more faithful animal model of aHUS-like 
disease than those generated to date (24, 36, 37), and this makes 
it particularly relevant for the testing of new anti-complement 
therapies. The data presented herein support the prevailing view 
that aHUS arises primarily due to deficient protection of host 
cellular and extracellular matrix surfaces from complement acti-
vation. This aHUS mouse model, based on a C3 gain-of-function 
amino acid substitution, offers opportunities to further dissect the 
precise role of complement and other factors that drive aHUS in 
Figure 6. Molecular basis of complement dysregulation in C3KI mice. SPR analysis using mouse C3b derived from WT or C3KI mouse plasma. Mouse C3b 
was amine coupled to a CM5 biosensor chip (930 ± 10 RU). Doubly diluted concentration series of (A) purified murine FH (0 to 10 μM), (B) recombinant 
murine FH SCRs 1–5 (0 to 14.6 μM), (C) recombinant human FH SCRs 19-20 (0 to 20 μM), or (D) recombinant murine Crry SCRs 1–5 (0 to 10 μM) were flowed 
across the chip surface. The equilibrium dissociation constant KD was calculated using a steady-state model in the Biacore evaluation package, indicated 
as the black vertical line. *At the concentration range assayed here, human FH19–20 was not able to achieve saturated binding on the C3b Asn1115 surface; 
thus, an underestimated KD is indicated by the red vertical line. (E) Representative gels showing plasma-purified murine C3, as indicated, incubated with 
human FI and FH in a fluid phase cofactor activity assay, with densitometry analysis (Image Studio version 5.2) of intact α chain shown below; shown is 
the average of 3 experiments ± SEM with unpaired t test.
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accumulating evidence that mutations that affect the functional 
properties of C3/C3b are associated not just with aHUS but also 
with membranoproliferative glomerulonephritis (MPGN)/C3G 
(39, 48–50), and defining that link remains of keen interest.
While we initially surveyed in vitro the functions of multiple 
candidate mutations in recombinant human C3, we were drawn to 
D1115N, since it maps to the binding interface between the TED 
of C3b and SCRs 19–20 of FH (38) but also results in complete 
loss of MCP binding when MCP is coated on a solid surface such 
as a sensor chip or ELISA well (26, 29). Our own analysis with 
recombinant human proteins, in which WT or variant C3(H20) 
was attached to a CM5 Biacore chip and FH or MCP used as ana-
lyte, confirmed these findings (Supplemental Figure 1). Reduced 
FH binding was also observed in both the human and mouse pro-
teins (Figure 6 and Supplemental Figures 1, 4, and 5). The clear 
affinity reductions observed in SPR studies of both recombinant 
(although not all) disease-associated mutations in human FH clus-
ter within SCRs 19–20, which are known to contain binding sites 
for C3d, the TED of C3b, and surface polyanions and to be crucial 
for distinguishing between self- and non-self-surfaces (46). Such a 
truncation of FH has, however, not been identified in humans.
In contrast, the present model derives from a single muta-
tion in a murine gene that maps directly to the equivalent dis-
ease-linked mutation in humans (26). Our starting point was 
the discovery that mutations in human C3 associated with aHUS 
encode amino acid substitutions that, in C3b, occur throughout 
the binding regions for FH, although there is a bias toward the 
region that binds to FH SCRs 19–20 (double the number found 
in the rest of C3), i.e., the TED of C3b. This clustering of aHUS-
linked mutations in C3 is not as prominent as it is in FH, in which 
there is a “hot spot” of aHUS-linked mutations within SCRs 19–20 
(4 times the number found in the rest of FH) (21, 29, 47). There is 
Figure 7. Treatment of the C3KI mice. (A) Kaplan-Meier survival curve analysis showing 100% survival in C3KI animals treated with BB5.1 (n = 8), in com-
parison to isotype control–treated animals (n = 11). (B) Where available, plasma creatinine values were analyzed. Shown are results for 7 C3KI mice treated 
with BB5.1 (C3KI + BB5.1, red triangles), 8 C3KI mice treated with isotype control antibody (C3KI + isotype, blue diamonds), and 15 untreated C3KI/WT 
mice (black squares). (C) Platelet counts of 8 C3KI mice treated with BB5.1 and 6 C3KI mice treated with isotype control antibody. Absolute numbers were 
provided by use of cell count beads and flow cytometry. (D) Frozen kidney sections were collected from C3KI mice treated with BB5.1 or isotype control 
antibody and stained for glomerular C3 (anti-C3, upper panels, original magnification, ×20) and C9 deposition (anti-C9, lower panels, original magnifica-
tion, ×10). Images are representative of 5 images per animal analyzed. (E) Top panels: PAS-stained sections from C3KI mice treated with BB5.1 and IgG con-
trol. Histology demonstrates features of a TMA. Original magnification, ×20. Representative of 8 BB5.1-treated animals and 6 IgG control-treated animals. 
Bottom panels: Electron microscopy images of BB5.1-treated animals and IgG control showing foot process effacement and subtle areas of subendothelial 
lucency. Original magnification, ×5000 (BB5.1), ×6000 (IgG). Representative of 2 C3KI BB5.1-treated and 2 C3KI IgG control–treated mice. *P < 0.05,  
**P < 0.005, ****P < 0.0001 using unpaired t test with Welch’s correction.
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human C3 in the context of MCP, but it may give important infor-
mation regarding the pathogenic burden of the loss of interaction 
with MCP versus FH. Clinically, MCP mutations rarely progress 
to end-stage renal disease (ESRD); this is in contrast to the poor 
renal prognosis associated with FH and C3 mutations (4, 15, 16). 
A failure of FH to engage fully with the TED is expected to be 
particularly detrimental to protection of host cell surfaces from 
excess complement activation. We also found evidence that C3b 
Asn1115 is marginally more resistant than WT C3b to fluid-phase 
FH- and FI-mediated cleavage (Figure 6E and Supplemental 
Figure 4). This, in concert with the MCP deficiency, apparent-
ly resulted in lower FB levels in one of the patients; in the mice, 
there was also evidence of increased FB consumption despite 
normal interaction with Crry (Figure 1 and Supplemental Figure 
7C). Interestingly, we also detected an increase in FH levels in the 
plasma of C3KI mice. This suggests a compensatory upregulation 
and ex vivo purified C3b Asn1115 are consistent with loss of an 
important C-terminal binding interaction but retention of the 
other FH (i.e., SCRs 1–5)-binding sites. Indeed, the affinity of full-
length mouse FH binding to rmC3b Asn1115 was almost identical 
to that for recombinant mFH SCRs 1–5 alone (or mouse Crry), and 
the loss of binding for human FH SCRs 19–20 appears to confirm 
the mechanism (Figure 6), consistent with the studies by Morgan 
et al. (38). These data suggest that the D1115N substitution of 
murine C3b primarily perturbs interactions with the C-terminus 
of FH and hence the ability of C3b Asn1115 to be regulated by FH 
and FI. This is somewhat surprising, based on the deficit in MCP 
binding noted with this change (Supplemental Figure 1) (26, 29). 
However, it is clear that the mutation has only subtle effects, if 
any, on the interaction of mouse C3b with Crry or the N-termi-
nus of FH. This likely reflects differences in the contact residues/
structures of mouse C3 in the context of Crry compared with 
Figure 8. C3KI phenotype is rescued through genetic deletion of complement C5. (A) Proteinuria measurements of urine collected from 3 C5KO mice 
premortem (black circles) and, 9 C3KI.C5KO mice at 6 months of age (green diamonds) as well as, 12 C3KI mice on P21–P28 (red triangles). (B) Creatinine 
values obtained from 3 C5KO mice, 10 C3KI.C5KO mice at 6 months old, and 19 C3KI mice. (C) Plasma C3 levels. (D) Immunofluorescence of glomerular C3 
deposition (upper panels; original magnification, ×20), with densitometry analysis of C3 deposition to the right, and with anti-C9 antibody (lower panels; 
original magnification, ×10). (E) MSB stain of C3KI.C5KO 6-month-old mice; original magnification, ×20 (representative of n = 8 examined). (F) PAS-stained 
sections of C3KI.C5KO 6-month-old mice showing normal glomeruli; original magnification, ×20 (representative of n = 8 examined). (G) Electron microsco-
py of a 6-month-old C3KI.C5KO mouse showing normal glomerular basement membrane and no evidence of dense deposits; original magnification, ×6000 
(representative of n = 4 examined). (H) Electron microscopy of a 6-month-old WT mouse showing normal glomerular basement membranes; original 
magnification, ×10,000 (representative of n = 4 examined). (I) Diff-Quik–stained blood film of a C3KI.C5KO 6-month-old mouse showing no evidence of 
fragmented red blood cells; original magnification, ×10 (representative of n = 8 examined). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Unpaired t 
test (C) with Welch’s correction (A, B, and D).
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ogy in the treated animals was not as unequivocal, as it showed 
that renal pathology remained. However, it is likely that more time 
is necessary to allow for full histological recovery. Therefore, we 
reasoned that extending our treatment study (mirroring clinical 
management) would lead to histological improvement, given the 
dramatic clinical improvement observed in the treatment cohort; 
thus, a pragmatic extension to this work was then to analyze the 
long-term effects of C5 blockade using the C5-knockout animals.
Eculizumab has revolutionized the treatment of patients with 
aHUS; however, we do not yet know nor will we know for some 
time what the long-term effects of this drug will be in our patient 
population. While inhibition at the level of C5 arrests disease, it 
does not target the effect of a persisting dysregulated alternative 
pathway and subsequent upregulation of C3. This is a vital ques-
tion to answer, as it translates to all complement mutations asso-
ciated with aHUS and could directly affect longevity of treatment. 
It has been hypothesized that over time patients on C5-inhibiting 
therapy may revert to a C3G due to sustained C3 activation. Our 
6-month mouse cohort provides us with what we believe to be the 
clearest evidence to date that long-term C5 inhibition is unlikely 
to result in an alternative complement-mediated renal disease, 
despite the presence of deposited C3 within the glomeruli. Six 
months of age in a mouse is the equivalent of 20 human years (55); 
thus, our data highlight that C5 blockade in patients for this time 
frame will be unlikely to lead to an alternative disease process.
Our results suggest that the present C3 gain-of-function 
mouse model of aHUS will allow evaluation of various comple-
ment-inhibiting therapies, for instance, targeting the ability of 
C5aR antagonists to reverse disease (56). This would allow the 
dissection of the independent roles of C5a and MAC in the patho-
genesis of disease with a clarity not achievable by other currently 
available models. Furthermore, the C3 gain-of-function model 
offers the potential to assess therapies targeting the alternative 
pathway directly, such as homodimeric minimal FH (57), CR2-FH 
(58), and anti-properdin (59), in what we believe to be the most 
realistic model of complement genetic alterations to date. One 
major aim of our studies is to help test therapeutics that can mit-
igate the increased risk of infections posed by long-term use of 
eculizumab (34, 60–62).
We have shown that the C3KI mouse mirrors the aHUS clinical 
phenotype. A similar complement profile, i.e., low C3 levels and 
elevated FH levels in plasma, was seen in both patients and mice. 
Highly similar histological and biochemical phenotypes further 
underline the extent to which this model recapitulates the clinical 
phenotype in humans. Interestingly, in mice only homozygotes 
developed spontaneous disease early in life, while patients are het-
erozygous for C3 Asn1115. This is consistent with the notion that 
the genetic change predisposes to the human disease, but an envi-
ronmental trigger is needed for development of the disease (15, 20, 
63). We tracked our C3KI/WT mice for 12 months, and to date there 
is no evidence that the animals developed disease, consistent with 
the environmental trigger hypothesis. While the absence of disease 
in the heterozygotes could be seen as a limitation of this study, we 
would argue that they represent a model to identify the factors 
beyond uncontrolled complement activation that drive aHUS, i.e., 
the C3KI/WT mice can be used to investigate a range of potential 
environmental and dietary triggers that can precipitate aHUS. Col-
of CFH expression in an attempt to regulate the mutant C3b or 
that CFH expression can be modulated by the C3-driven inflam-
matory response. This observation is consistent with the mouse 
FH W1206R model of TMA, in which elevated FH levels were 
also observed (37). Notably, both NRCTC patients with the C3 
Asn1115 mutation possessed plasma levels of FH above the nor-
mal range on the majority of readings, reaffirming the parallels of 
our model to human disease.
It is clear from previous work with transgenic mice that a more 
substantial plasma C3 depletion than that seen in the C3KI mice 
may lead to the alternative phenotype of MPGN/C3G (36, 41, 47). 
Moreover, normal fluid-phase regulation is preserved in all of the 
mouse models of aHUS reported to date (24, 37, 51). The pheno-
type we obtained is that of aHUS, as evidenced by the histologi-
cal features of a renal TMA rather than C3G. We therefore infer 
that any enhanced resistance to fluid-phase cleavage by FI of C3b 
Asn1115 is not a major contributor to the disease-like symptoms 
observed in our model. Lower plasma C3 levels are seen in many 
aHUS humans with C3 mutations (26, 29). The lower C3 levels in 
our murine model are fully consistent with previously published 
mouse models of a TMA (24, 37).
Thus, we can conclude that in the C3KI mouse, once C3b 
Asn1115 is deposited on a surface, a positive feedback process can 
operate that is neither controllable by FH nor restricted by a short-
age of C3. This leads to extensive C3b deposition and activation 
of the terminal pathway, as evidenced from our observation of C5 
consumption coupled with glomerular C9 deposition (Figure 5, B 
and C). Thus, our data emphasize the delicate balance of comple-
ment regulation; disease develops when the balance is disturbed 
and the threshold of regulatory ability is breached. Our C3KI ani-
mals retain the C3 “resources” to overwhelm complement regula-
tion at the cell surface despite plasma C3 levels being lower than 
those in their WT counterparts.
Our model of C3 convertase dysregulation has parallels with 
that in a study by the Song group, in which the aHUS-linked single 
amino acid substitution W1206R was transferred from human FH 
into murine FH (37). Homozygous FH W1206R mice developed a 
renal phenotype consistent with aHUS, but a subtantial proportion 
of animals also demonstrated an aggressive TMA, with notable 
thrombus found in multiple organs. Analysis of key organs in C3KI 
animals revealed no evidence of large thrombi or microthrom-
bi, although we did not perform an exhaustive search. Across our 
study, 3 homozygous mice (of ~45 analyzed) showed symptoms 
consistent with stroke, but this was always in the clinical context 
of severe kidney failure and likely driven by hypertension. Thus, in 
these two models of aHUS, the mechanisms driving the fatal out-
come likely differ substantially.
Given the successful use of C5 inhibition in aHUS patients (3, 
35, 52–54) coupled with previous work showing that the disease 
is dependent on C5 (25), we sought to further validate our model 
through use of the murine C5 inhibitor BB5.1. As predicted, this 
rescued the phenotype, with 100% survival in C3KI mice at 30 
days postpartum. While C3 fragment deposition in the kidney of 
BB5.1-treated mice appeared unchanged, there was a reduction 
in glomerular C9 deposition. This suggests that C5a and/or MAC 
are critical to the endothelial dysfunction and subsequent devel-
opment of a TMA. Unfortunately, our analysis of kidney morphol-
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glycol (PEG) followed by application onto a Mono Q anion- exchange 
column (GE, HR5/5) and gel filtration chromatography using a 
HiLoad 16/600 Superdex 200 pg column. WT and mutant mouse C3 
protein (C3 Asn1115) concentrations were calculated by measuring 
absorbance at 280 nm using an extinction coefficient of 183,033 and 
a molecular weight of 186.48 kDa as determined from the mature WT 
amino acid sequence (see Supplemental Figure 2A) using the ExPASy 
ProtParam tool. Reducing and nonreducing SDS-PAGE gels were used 
to provide evidence of homogeneity.
Mouse FH. Murine FH was purified from 20 ml mouse serum using 
a previously generated mAb (2A5, anti-mouse FH, a gift from Claire 
Harris, Newcastle University) affinity chromatography resin using an 
ÄKTA Start (GE), followed by gel filtration chromatography on HiLoad 
16/600 Superdex 200 pg column.
SDS-PAGE and Western blotting
Gels with the appropriate percentage of acrylamide were freshly pre-
pared for each SDS-PAGE run. Samples containing recombinant or 
plasma-derived C3 were run under both nonreducing and reducing 
conditions. Protein bands were either stained using Coomassie blue 
or were transferred to nitrocellulose. The nitrocellulose was blocked 
in 5% w/v nonfat milk in PBS overnight at 4°C, then exposed to a poly-
clonal goat anti–mouse C3 antibody–HRP (1:10,000; catalog 55557, 
lot 06803, MP Biomedicals). After extensive washing in 0.01% v/v 
Tween in PBS, the nitrocellulose was then developed using Bio-Rad 
Clarity Western ECL substrate, followed by detection/analysis on the 
Odyssey FC imaging system (LI-COR).
Fluid-phase cofactor activity assays
See Supplemental Methods.
SPR
All experiments were conducted on a BIAcore S200. Each version of 
murine C3 was converted to C3b, via incubation with purified human 
FB and FD (at molar concentrations 50 and 1000 times less, respec-
tively, than that of C3) at 37°C in PBS supplemented with 1 mM MgCl2 
for 1 hour. The incubated samples were gel filtrated using a Superdex 
200 10/300 GL column; C3b-containing fractions were pooled and 
concentrated. Each version of murine C3b (i.e., WT C3b and C3b 
Asn1115) was immobilized (930 ± 10 RU) on separate flow cells of a 
CM5 chip using standard amine coupling. A 2-fold dilution series of 
purified murine FH (10 to 0 μM), recombinant murine FH SCRs 1–5 
(14.6 to 0 μM), recombinant human FH SCRs 19–20 (20 to 0 μM), or 
recombinant murine Crry SCRs 1–5 (10 to 0 μM) was made in HBST 
buffer (10 mM HEPES, 150 mM NaCl, and 0.005% Tween-20, pH 7.4) 
and flowed across either chip surface in the same buffer. All analytes 
were injected in duplicate (30 μl/minutes for 200 seconds), followed 
by running buffer for 300 seconds and a regeneration phase involving 
injection of regeneration buffer (10 mM sodium acetate, 1 M NaCl, 
pH 4.5) for 60 seconds. The equilibrium dissociation constant, KD, 
and standard error were calculated using the steady-state model in 
BIAcore S200 Evaluation Software.
ELISA
Murine C3. To determine mouse C3 levels, mAb 11H9 (recognizing 
both intact C3 and its cleaved products C3b, iC3b, C3d, and C3dg; 
catalog HM1045, Hycult Biotech via Cambridge Bioscience) was 
lectively, our spontaneous and likely inducible model will enable 
testing of a variety of complement-inhibiting therapies, and impor-
tantly, testing of withdrawal of therapy and remission monitoring. 
This has the potential to culminate in a wealth of translational data 
that will directly inform future clinical trials and targeted therapies, 
with the overall aim of outcome of improving outcome in patients 
with complement-mediated diseases.
In summary, our mouse model of aHUS, engineered by using 
a single point mutation in C3, recapitulates the clinical phenotype 
found in humans. This C3 mutation results in systemic comple-
ment activation and endothelial dysfunction, culminating in a 
renal TMA. Our model provides the opportunity to investigate 
the roles played by various players downstream of C3 activation 
and is a test bed for future complement therapeutics. Developing 
a therapy to restore complement homeostasis would, in addition, 
be transferable to several other endothelial damage–mediated dis-
eases for which therapy remains an unmet clinical need.
Methods
Mice
B6.C3Tm1(D1115N)Oz/NCL (C3KI) mice were generated using standard 
knockin technology by Ozgene (see Supplemental Figure 5) and 
backcrossed onto constitutive Cre recombinase–expressing mice 
(B6OZCre; Ozgene) or constitutive FLPe recombinase–transgene 
mice (B6OzFlpe; Ozgene). These F1 C3KI/CRE mice were shipped 
to Newcastle and intercrossed to provide homozygous C3KI mice. 
Genotyping of C3KI mice was performed by PCR on digested 
ear notch tissue using the following strategy devised by Ozgene. 
Primer pairs 5′-CCTTCTCTTTCTGGAATTTGCCTG-3′ and 
5′-CTTTGGTGACCCTGTCTGTTCC-3′ were used in 30 cycles of 
PCR (58°C annealing temperature), generating a 574-bp product 
in the case of native C3 and a 633-bp product for the knocked-in 
sequence. The 633-bp product was digested into fragments of 402 
bp and 231 bp by incubating with restriction enzyme SpeI. Using 
a 2% agarose gel, amplicons were separated sufficiently to allow 
identification of WT or the C3KI gene carriers. The presence of 
the Cre recombinase gene was detected through use of the follow-
ing PCR primers: 5′-ATTTACGGCGCTAAGGATGACTC-3′ and 
5′-TTACACCTGTTCAATTCCCCTG-3′, which generated a 680-
bp amplicon in 30 cycles of PCR (58°C annealing temperature) 
(designed at Ozgene). FH-knockout mice (FH-KO, ref. 41) were 
generated by our research team. C3KI mice were backcrossed onto 
the previously described C5-deficient mice (C5KO; via Matthew 
Pickering) (25). In brief, C3KI/WT were crossed with C5KO mice. 
Pups were then all C5KO/WT, and those that were also C3KI/WT 
were crossed with C5KO mice. Pups from this cross were screened 
by PCR using DBA primers: 5′-CACGATAATGGGAGTCATCTG-
CG-3′ and 5′-AAGTTGGAGTGTGGTCTTTGGGCC-3′, followed 
by a HindIII digest to distinguish between WT, +/–, and –/– gen-
otypes. Pups that were C3KI/WT.C5KO were then crossed to pro-
duce C3KI.C5KO mice.
Protein purification
Murine C3 from plasma. Mouse C3 for biochemical analysis was puri-
fied from mouse plasma according to the method of Van den Berg et al. 
(64). Briefly, 10 ml mouse serum was precipitated using polyethylene 
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Histological analysis
Light microscopy. Kidneys were harvested and fixed in 10% buffered 
formalin solution. Following fixation, the tissues were embedded in 
paraffin, then cut in 3-μm sections. Sections were stained with PAS 
reagent, then examined by light microscopy. Newcastle Hospitals 
NHS pathology laboratories stained for fibrin using a standard MSB 
stain protocol. Sections were blinded to avoid interpreter bias.
Immunofluorescence. Mouse kidneys were snap-frozen in isopen-
tane (pre-cooled in liquid nitrogen) and stored at –80°C in individual 
containers. Five-micrometer cyrosections from mouse kidneys were 
mounted on a Shandon ColorFrost Plus microscope slide (Thermo 
Fisher Scientific), before fixing in acetone and stored in –80°C. The 
thawed tissue sections were blocked for an hour with 60 μl of 20% 
(v/v) goat serum in PBS, then detected with 60 μl FITC-conjugated 
goat polyclonal anti–mouse C3 antibody (catalog 0855500, MP Bio-
medicals, 1:100). After repeated washing with PBS, the tissue sections 
were stained with DAPI (catalog H-1200, Vector Laboratories) and 
covered with glass coverslips. Fluorescence images were taken at ×10 
or ×20 magnification utilizing a Zeiss Axio Imager II.
For C9 immunofluorescence, sections were blocked with rabbit 
and goat serum, followed by rat anti–mouse CD16/CD32 Fc block (cat-
alog 553141, BD Pharmingen 1:100) in 2% w/v BSA in PBS for 1 hour at 
room temperature. After washing, sections were incubated with rabbit 
anti–rat C9 (1:75, a gift from B.P. Morgan, Cardiff University, Cardiff, 
United Kingdom) overnight at 4°C. The next day, sections were washed, 
then incubated with goat anti-rabbit Alexa Fluor 594 (1:100, catalog 
A-11012, Abcam). Finally, the sections were washed, mounted in DAPI, 
and imaged as above. Immunofluorescence images were analyzed in 
ImageJ (NIH) and expressed as relative fluorescence units (RFU).
Electron microscopy. Small pieces of cortical tissue (1 mm3) were 
fixed in 2% w/v glutaraldehyde in 0.1 M cacodylate buffer, post-
fixed in osmium tetroxide, dehydrated in a graded series of acetone, 
and embedded in Taab epoxy resin. Ultrathin sections (70 nm) were 
picked up on copper grids, stained with uranyl acetate and lead citrate, 
and examined using a Philips CM100 transmission electron micro-
scope (EM Research Services, Newcastle University).
Availability of data and materials. The C3KI conditional/constitutive 
mouse and recombinant mouse C3 plasmid/protein are available through 
a material transfer agreement (MTA) with Newcastle University.
Statistics
Data were analyzed using GraphPad Prism 7.00 for Windows (Graph-
Pad Software). Densitometry was carried out using Image studio ver-
sion 5.2 (LI-COR). Groups were compared at each time point using 
1- or 2-way ANOVA with Bonferroni’s multiple-comparisons test as 
indicated. A P value less than 0.05 was considered significant; *P < 
0.05, **P < 0.01, ***P < 0.0005. Student’s t test was 2-tailed, and data 
are shown as mean ± SEM.
Study approval
All animal experiments were approved by the ethics committee of 
the Comparative Biology Centre of Newcastle University and per-
formed under the United Kingdom’s Home Office granted license 
PD86B3678. The clinical study involving subjects from the NRCTC 
was approved by the Northern and Yorkshire Multi-Centre Research 
Ethics Committee, and informed consent obtained in accordance with 
the Declaration of Helsinki.
coated on each well of a Nunc MaxiSorp flat-bottom ELISA plate (20 
ng/well) to capture mouse C3. Then 50 μl of a 1:800-diluted sample 
was applied for analysis. Bound C3 was detected through use of an 
HRP-conjugated goat polyclonal anti–mouse C3 antibody (1:25,000, 
catalog 55557, lot 06803, MP Biomedicals). This dilution biases the 
assay to detect bound intact C3. The ELISA was developed with TMB. 
The C3 concentrations were interpreted based on a standard curve 
generated using purified WT mouse C3 and interpolated using Graph-
Pad Prism software.
FH. To measure FH present in mouse plasma, ELISA plates (Nunc) 
were coated with monoclonal anti-FH (2A5) at 1 μg/ml. After over-
night incubation at 4°C, plates were blocked with 1% w/v BSA at room 
temperature for 1 hour. After washing, plates were incubated with 
diluted mouse plasma (1:1000) for 1 hour at room temperature. Plates 
were washed and then incubated with sheep anti–mouse FH (1:5000, 
Abcam Ab8842) for 1 hour at room temperature and then detected by 
adding donkey anti-sheep HRP-conjugated antibody (1:5000, 713-
035-147, lot 125113, Jackson ImmunoResearch Laboratories Inc. via 
Stratech Scientific) for 1 hour at room temperature. A standard curve 
was compiled using the known concentration of purified mouse CFH.
C5. To measure C5 present in mouse plasma, ELISA plates were 
coated with 1 μg/ml BB5.1 (anti-C5, catalog HM1073, Hycult Biotech 
via Cambridge Biosciences). After overnight incubation at 4°C, plates 
were blocked with 1% w/v BSA at room temperature for 1 hour and 
then washed. Plates were then incubated with diluted mouse plasma 
(1:1000) for 1 hour, washed, and then incubated with goat anti–human 
C5 (1:1000, Quidel A306, 073139). Plates were then incubated with 
donkey anti-goat HRP-conjugated antibody (1:5000, 705-036-147, lot 
124700 Jackson ImmunoResearch Laboratories Inc. via Stratech Sci-
entific). After a final wash, the plate was developed with TMB. Sam-
ples were standardized to WT control.
Assessment of murine renal function and hematological parameters
Plasma creatinine was measured by collecting plasma by cardiac 
puncture into EDTA and subsequently measured on a Cobas 602 
analyzer in the Newcastle Hospitals NHS laboratories. Plasma urea 
was measured using a urea assay kit (MAK006, Sigma-Aldrich). 
Mouse urine was collected and measured for hematuria and protein-
uria using Hema-Combistix (Siemens/Bayer). Platelet analysis was 
performed by flow cytometry. Briefly, 10 μl EDTA-blood was mixed 
with 400 μl red cell lysis buffer (Sigma-Aldrich) and incubated for 
10 minutes at room temperature. An aliquot of 5 μl was then trans-
ferred to 1 ml flow buffer (PBS containing 5% w/v BSA, 1 mM EDTA, 
0.1% w/v Na azide) and washed at 1000 g for 5 minutes, 3 times, and 
resuspended in 200 μl flow buffer containing 1:400 CD41-FITC, 
1:800 CD61-PE, and 1:800 CD62P- BV421 (catalog 553848, 553347, 
and 564289, respectively, BD Biosciences). Samples were incubated 
for an hour on ice in the dark before washing 3 times with 3 ml flow 
buffer (1000 g for 5 minutes). Finally, samples were resuspended in 
250 μl of 1% w/v paraformaldehyde/flow buffer with 25 μl Count-
Bright beads (i.e., 2.5 × 104 beads per tube; Invitrogen). Data were 
collected using a FACSCanto flow cytometer and analyzed on FCS 
Express, version 6 (De Novo Software). Alternatively, platelets were 
analyzed by using an improved Neubauer hemocytometer through 
addition of 25 μl of the red cell lysed solution (as above) and allowing 
the sample to settle for 10 minutes before counting as per the manu-
facturer’s instructions.
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